Biomica

Executive Summary

Biomica is a clinical-stage Israeli biotech subsidiary of Evogene, dedicated to developing microbiome-based therapeutics for oncology. The company leverages its computational biology platform to design live biotherapeutic products (LBPs) that modulate the gut microbiome, thereby enhancing anti-tumor immunity. Its lead candidate, BMC128, targets renal cell carcinoma and non-small cell lung cancer, and has successfully completed a Phase 1 safety trial, demonstrating a favorable safety profile. With a novel approach that aims to improve responses to checkpoint inhibitors, Biomica addresses the significant unmet need in resistant solid tumors. The company is now poised to initiate Phase 2 studies and expand its pipeline into additional indications. Backed by Evogene’s technology and resources, Biomica is well-positioned in the emerging field of microbiome-based immuno-oncology. Near-term priorities include progressing BMC128 into efficacy trials, exploring biomarker-driven patient stratification, and pursuing strategic partnerships to accelerate development. While still in early clinical stages, the completion of Phase 1 de-risks the platform and validates its potential to modulate the immune system via the gut microbiome.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 2 Trial for BMC12870% success
• TBDPresentation of Phase 1 Data at Major Oncology Conference80% success
• TBDPotential Partnership or Licensing Deal for BMC12850% success